English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
Tag: multiple myelmoma
Memorial Sloan Kettering – Hackensack Meridian Health Partnership Announces Funding for Inaugural Immunology Research Collaboration Projects
The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers’ projects were selected in 2020 for funding support.
IU cancer researcher earns $1.6 million NCI grant for multiple myeloma bone disease therapies
David Roodman is leading research to investigate a molecule that could repair bone, decrease tumors and improve outcomes for multiple myeloma patients on specific targeted therapies.
John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma
Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory (persistent) multiple myeloma. The study was selected as the prestigious plenary presentation at the 61st American Society of Hematology (ASH) Annual Meeting, the world’s leading conference for hematologic cancers and blood disorders, held in Orlando in December.